Urine VOCs From DKD and Nephrotic Syndrome PateintsVOCs in DKDNCT07137351
The Biosensor Using the Target Urine VOCs for Detecting DKD Diabetic Kidney Disease
An observational study of Urine VOCs From DKD and Nephrotic Syndrome Pateints, run by Suranaree University of Technology at 1 site in Thailand.
Trial summary
Volatile organic compounds (VOCs) are easily evaporated substances produced by pathophysiologic metabolism and have been utilized in research as potential new biomarkers for differentiating various diseases, acting as the odor imprints of each disease. Read more about this study
- Who is it for?
- Ages 20 years and olderHealthy volunteers can take part
- Conditions the study is for
- Urine VOCs From DKD and Nephrotic Syndrome Pateints
- What is being tested?
- The Biosensor Using the Target Urine Volatile Organic Compounds
- How many people
- 0 participants
- Where
- 1 siteThailand
- Study dates
- 12 May 2025to 13 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: This study was a descriptive cohort study. General data such as age, gender, medications, other medical conditions, or chronic diseases that might have affected the urine VOCs test were reviewed and recorded from the medical records of subjects who attended the outpatient clinic of the Internal Medicine department at the Suranaree University of Technology Hospital from March 2024 to July 2024. Urine samples from diabetic patients, both with and without abnormal proteinuria, were compared with normal urine samples and urine samples from patients with NS from other causes.
Who may be able to join
- Age > 20 years
- In DKD and NS groups must undergone renal biopsy before study
Who cannot join
- Patients with an estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m2
- Pregnancy
- Ambiguous pathological results
Trial locations and contacts
1 site in 1 country.
Thailand1 site
Institute of Medicine, Suranaree University of Technology
Nakhon Ratchasima, 30000
About this study
Official title: The Biosensor Using the Target Urine Volatile Organic Compounds for Detecting Diabetic Kidney Disease
Volatile organic compounds (VOCs) are easily evaporated substances produced by pathophysiologic metabolism and have been utilized in research as potential new biomarkers for differentiating various diseases, acting as the odor imprints of each disease.
Researchers used metal oxide semiconductors to examine the properties of VOCs produced by diabetic kidney disease patients. Also, the VOCs of those with diabetic kidney disease were then compared with those of healthy individuals and patients with nephrotic syndrome.
The study found that VOCs primarily composed of hydrogen, methanol, and sulfate in diabetic kidney disease patients had a significantly different ability to release free electrons from the metal oxide semiconductors compared to healthy individuals and patients with nephrotic syndrome from other causes. This finding suggested that VOCs could be used as biomarkers which could lead to the replacement of renal biopsy for diagnosis in the future.
Read the detailed description
This study was a descriptive cohort study. General data such as age, gender, medications, other medical conditions, or chronic diseases that might have affected the urine VOCs test were reviewed and recorded from the medical records of subjects who attended the outpatient clinic of the Internal Medicine department at the Suranaree University of Technology Hospital from March 2024 to July 2024. Urine samples from diabetic patients, both with and without abnormal proteinuria, were compared with normal urine samples and urine samples from patients with NS from other causes.
- Being tested
- The Biosensor Using the Target Urine Volatile Organic Compounds
- Keywords
- VOCs, Biosensor, diabetic kidney disease, nephrotic syndrome
- Medical subject headings
- Diabetic Nephropathies, Nephrotic Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
The Biosensor Using the Target Urine Volatile Organic CompoundsDiagnostic test
Also called Metal oxide semiconductor detecting VOCs
The authors opted to utilize five distinct commercially available semiconductors (metal oxide sensors) to detect all the targeted VOCs which were manufactured by Figaro company.
Urine samples from patients were placed in a urine container, which was then placed into the VOCs detection device. The lid was closed, and the system was set to operate in a closed-loop mode at a room temperature of 25 degrees Celsius. The device then vacuumed VOCs from the urine samples of the patients through a gas tube into the biosensor chamber located on top, where analysis was performed.
| Study group | Role | What they receive |
|---|---|---|
| 3 | ็Healthy volunteer, DKD pateints, other causes of Nephrotic syndrome Receives: Diagnostic Test: The Biosensor Using the Target Urine Volatile Organic Compounds | |
| ็Healthy volunteer | ็Healthy volunteer = normal subject or diabetes pateint without proteinuria (< 300 mg/day) Receives: Diagnostic Test: The Biosensor Using the Target Urine Volatile Organic Compounds | |
| DKD pateints | DKD = diabetic kidney disease with proteinuria (> 1 g/day) with confirmed by pathological results Receives: Diagnostic Test: The Biosensor Using the Target Urine Volatile Organic Compounds | |
| other causes of Nephrotic syndome | NS = other casues of nephrotic syndrome, pateints must have with proteinuria > 3.5 g/day) with confirmed by pathological results. In addition, They must have no DM in the illness profile. Receives: Diagnostic Test: The Biosensor Using the Target Urine Volatile Organic Compounds |
What is being measured
The primary outcome is the main question the study is designed to answer.
Characteristic of VOCs in DKD
Electrical resistance characteristic VOCs by semiconductors in DKD when compared to normal and NS
Measured: March 2024- July 2024
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Aug 2025
- Study start12 May 2025
- Primary completion12 May 2025
- Study completion13 May 2025
Why it stopped: This record was initially withdrawn due to incomplete protocol section. The study was completed and published, and a corrected version will be submitted under a new record
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Urine VOCs From DKD and Nephrotic Syndrome PateintsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Suranaree University of Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chatchai Kreepala, MD, Suranaree University of Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07137351
- Sponsor's protocol ID
- EC-67-0001
- Acronym
- VOCs in DKD
- Status last verified
- Aug 2025
- First submitted
- 7 Jun 2024
- Last updated
- 22 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: the urine samples were indentided by some special code and not allowed to share with other researches.
Study at a glance
From the registry record, last updated by the sponsor on 22 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Biosensor Using the Target Urine Volatile Organic Compounds for Detecting Diabetic Kidney Disease
- ClinicalTrials.gov ID
- NCT07137351
- Acronym / sponsor ID
- VOCs in DKD / EC-67-0001
- Keywords
- VOCs, Biosensor, diabetic kidney disease, nephrotic syndrome
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: This record was initially withdrawn due to incomplete protocol section. The study was completed and published, and a corrected version will be submitted under a new record
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Suranaree University of TechnologyUniversity, hospital or other
- Study start
- 12 May 2025 (actual)
- Primary completion
- 12 May 2025 (actual)
- Study completion
- 13 May 2025 (actual)
- First posted
- 22 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Volatile organic compounds (VOCs) are easily evaporated substances produced by pathophysiologic metabolism and have been utilized in research as potential new biomarkers for differentiating various diseases, acting as the odor imprints of each disease.
Researchers used metal oxide semiconductors to examine the properties of VOCs produced by diabetic kidney disease patients. Also, the VOCs of those with diabetic kidney disease were then compared with those of healthy individuals and patients with nephrotic syndrome.
The study found that VOCs primarily composed of hydrogen, methanol, and sulfate in diabetic kidney disease patients had a significantly different ability to release free electrons from the metal oxide semiconductors compared to healthy individuals and patients with nephrotic syndrome from other causes. This finding suggested that VOCs could be used as biomarkers which could lead to the replacement of renal biopsy for diagnosis in the future.
Detailed description
This study was a descriptive cohort study. General data such as age, gender, medications, other medical conditions, or chronic diseases that might have affected the urine VOCs test were reviewed and recorded from the medical records of subjects who attended the outpatient clinic of the Internal Medicine department at the Suranaree University of Technology Hospital from March 2024 to July 2024. Urine samples from diabetic patients, both with and without abnormal proteinuria, were compared with normal urine samples and urine samples from patients with NS from other causes.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| 3 | – | Diagnostic Test: The Biosensor Using the Target Urine Volatile Organic Compounds็Healthy volunteer, DKD pateints, other causes of Nephrotic syndrome |
| ็Healthy volunteer | – | Diagnostic Test: The Biosensor Using the Target Urine Volatile Organic Compounds็Healthy volunteer = normal subject or diabetes pateint without proteinuria (< 300 mg/day) |
| DKD pateints | – | Diagnostic Test: The Biosensor Using the Target Urine Volatile Organic CompoundsDKD = diabetic kidney disease with proteinuria (> 1 g/day) with confirmed by pathological results |
| other causes of Nephrotic syndome | – | Diagnostic Test: The Biosensor Using the Target Urine Volatile Organic CompoundsNS = other casues of nephrotic syndrome, pateints must have with proteinuria > 3.5 g/day) with confirmed by pathological results. In addition, They must have no DM in the illness profile. |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- This study was a descriptive cohort study. General data such as age, gender, medications, other medical conditions, or chronic diseases that might have affected the urine VOCs test were reviewed and recorded from the medical records of subjects who attended the outpatient clinic of the Internal Medicine department at the Suranaree University of Technology Hospital from March 2024 to July 2024. Urine samples from diabetic patients, both with and without abnormal proteinuria, were compared with normal urine samples and urine samples from patients with NS from other causes.
Key inclusion criteria (2 listed)
- Age > 20 years
- In DKD and NS groups must undergone renal biopsy before study
Key exclusion criteria (3 listed)
- Patients with an estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m2
- Pregnancy
- Ambiguous pathological results
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| The Biosensor Using the Target Urine Volatile Organic CompoundsAlso: Metal oxide semiconductor detecting VOCsThe authors opted to utilize five distinct commercially available semiconductors (metal oxide sensors) to detect all the targeted VOCs which were manufactured by Figaro company. Urine samples from patients were placed in a urine container, which was then placed into the VOCs detection device. The lid was closed, and the system was set to operate in a closed-loop mode at a room temperature of 25 degrees Celsius. The device then vacuumed VOCs from the urine samples of the patients through a gas tube into the biosensor chamber located on top, where analysis was performed. | Diagnostic test | 3, DKD pateints, other causes of Nephrotic syndome, ็Healthy volunteer |
Primary outcome
Characteristic of VOCs in DKD
Time frame: March 2024- July 2024
Electrical resistance characteristic VOCs by semiconductors in DKD when compared to normal and NS
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Aug 2025.
- Individual participant dataSharing planned: No. the urine samples were indentided by some special code and not allowed to share with other researches.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Urine VOCs From DKD and Nephrotic Syndrome Pateints, run by Suranaree University of Technology at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 22 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Characteristic of VOCs in DKD (time frame: March 2024- July 2024). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2025.